Redoxis is a CRO with core competence and experience in models for autoimmune diseases including Rheumatoid Arthritis (RA), Multiple Sclerosis (MS) and Guillain-Barré Syndrome (GBS) . We provide both commonly used and more specialised animal models for efficacy or MoA evaluation and tailor each study for your specific need.
With a fully equipped lab, Redoxis can add more value into your preclinical studies. We offer a wide range of In Vitro/ex vivo immunological assays and analyses, including T cell proliferation, cytokine profiling, chemotaxis assays, oxidation and ROS production and cell toxicity studies.
Since May 1st Malin Hultqvist Hopkins, former CSO, is appointed CEO of Redoxis. This change is in line with Redoxis continuous ambition to be a focused and efficient CRO specialising on preclinical autoimmune and inflammatory models in vitro and in vivo. Former CEO, Peter Olofsson, is since April 1st CEO of Redoxis R&D focused subsidiary […]
Since BioEurope is one of the main events for partnering and drug development collaborations, Redoxis is during 4-6 April in Stockholm attending the BioEurope event where we are meeting new partners, Sponsors for Redoxis preclinical capacities for autoimmune conditions. We are also initiating work in the subsidiary company ProNoxis to meet partners for co-development of […]
At Redoxis, we have a fully equipped lab for work with both primary cells and cell lines. We also hava fully equipped laboratory for post experiment follow up analyses and stand alone immunology assays. We have during the fall further enhanced our capacity for such studies by acquiring an Attune NxT flow cytometer (Thermo Fisher […]
In the 9th of December we will attend the PHARMA OUTSOURCING meeting in Stockholm- This is a new annual international partnering meeting for Investment Managers and R&D professionals in biotech-, pharma-, virtual- and start up companies to meet, network and discuss best practices in pharma outsourcing.